Skip to main content
Top
Published in: BMC Nephrology 1/2022

Open Access 01-12-2022 | Liver Transplantation | Research

Prediction of chronic kidney disease after orthotopic liver transplantation: development and validation of a nomogram model

Authors: Dandan Guo, Huifang Wang, Jun Liu, Hang Liu, Ming Zhang, Zixuan Fu, Xuemei Liu

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Background

We aimed to develop and validate a nomogram model for predicting CKD after orthotopic liver transplantation (OLT).

Methods

The retrospective data of 399 patients who underwent transplantation and were followed in our centre were collected. They were randomly assigned to the training set (n = 293) and validation set (n = 106). Multivariable Cox regression analysis was performed in the training set to identify predictors of CKD. According to the Cox regression analysis results, a nomogram model was developed and validated. The renal function of recipients was monitored, and the long-term survival prognosis was assessed.

Results

The incidence of CKD at 5 years after OLT was 25.6%. Cox regression analysis identified several predictors of post-OLT CKD, including recipient age at surgery (HR 1.036, 95% CI 1.006-1.068; p = 0.018), female sex (HR 2.867, 95% CI 1.709-4.810; p < 0.001), preoperative hypertension (HR 1.670, 95% CI 0.962-2.898; p = 0.068), preoperative eGFR (HR 0.996, 95% CI 0.991-1.001; p = 0.143), uric acid at 3 months (HR 1.002, 95% CI 1.001-1.004; p = 0.028), haemoglobin at 3 months (HR 0.970, 95% CI 0.956-0.983; p < 0.001), and average concentration of cyclosporine A at 3 months (HR 1.002, 95% CI 1.001-1.003; p < 0.001). According to these parameters, a nomogram model for predicting CKD after OLT was constructed and validated. The C-indices were 0.75 and 0.80 in the training and validation sets. The calibration curve of the nomogram showed that the CKD probabilities predicted by the nomogram agreed with the observed probabilities at 1, 3, and 5 years after OLT (p > 0.05). Renal function declined slowly year by year, and there were significant differences between patients divided by these predictors. Kaplan-Meier survival analysis showed that the survival prognosis of recipients decreased significantly with the progression of renal function.

Conclusions

With excellent predictive abilities, the nomogram may be a simple and reliable tool to identify patients at high risk for CKD and poor long-term prognosis after OLT.
Literature
1.
go back to reference Kim WR, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 annual data report: liver. Am J Transplant. 2014;14(Suppl 1):69–96.CrossRef Kim WR, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 annual data report: liver. Am J Transplant. 2014;14(Suppl 1):69–96.CrossRef
2.
go back to reference Giusto M, Berenguer M, Merkel C, et al. Chronic kidney disease after liver transplantation: pretransplantation risk factors and predictors during follow-up. Transplantation. 2013;95:1148–53.CrossRef Giusto M, Berenguer M, Merkel C, et al. Chronic kidney disease after liver transplantation: pretransplantation risk factors and predictors during follow-up. Transplantation. 2013;95:1148–53.CrossRef
3.
go back to reference Weber ML, Ibrahim HN, Lake JR. Renal dysfunction in liver transplant recipients: evaluation of the critical issues. Liver Transpl. 2012;18:1290–301.CrossRef Weber ML, Ibrahim HN, Lake JR. Renal dysfunction in liver transplant recipients: evaluation of the critical issues. Liver Transpl. 2012;18:1290–301.CrossRef
4.
go back to reference Hao JC, Wang WT, Yan LN, et al. Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation. World J Gastroenterol. 2014;20:11356–62.CrossRef Hao JC, Wang WT, Yan LN, et al. Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation. World J Gastroenterol. 2014;20:11356–62.CrossRef
5.
go back to reference Maurel P, Prémaud A, Carrier P, et al. Evaluation of longitudinal exposure to tacrolimus as a risk factor of chronic kidney disease occurrence within the first year post-liver transplantation. Transplantation. 2020;105:1585–94.CrossRef Maurel P, Prémaud A, Carrier P, et al. Evaluation of longitudinal exposure to tacrolimus as a risk factor of chronic kidney disease occurrence within the first year post-liver transplantation. Transplantation. 2020;105:1585–94.CrossRef
6.
go back to reference Li Y, Li B, Wang W, et al. Risk factors for new-onset chronic kidney disease in patients who have received a liver transplant. Exp Ther Med. 2018;15:3589–95.PubMedPubMedCentral Li Y, Li B, Wang W, et al. Risk factors for new-onset chronic kidney disease in patients who have received a liver transplant. Exp Ther Med. 2018;15:3589–95.PubMedPubMedCentral
7.
go back to reference Cantarovich M, Tchervenkov J, Paraskevas S, et al. Early changes in kidney function predict long-term chronic kidney disease and mortality in patients after liver transplantation. Transplantation. 2011;92:1358–63.CrossRef Cantarovich M, Tchervenkov J, Paraskevas S, et al. Early changes in kidney function predict long-term chronic kidney disease and mortality in patients after liver transplantation. Transplantation. 2011;92:1358–63.CrossRef
8.
go back to reference Bahirwani R, Reddy KR. Outcomes after liver transplantation: chronic kidney disease. Liver Transpl. 2009;15(Suppl 2):S70–4.CrossRef Bahirwani R, Reddy KR. Outcomes after liver transplantation: chronic kidney disease. Liver Transpl. 2009;15(Suppl 2):S70–4.CrossRef
9.
go back to reference Peng JC, Li YJ, Wang J, et al. Incidence of chronic kidney disease after orthotopic liver transplantation in a Chinese cohort. Clin Exp Nephrol. 2020;24:806–12.CrossRef Peng JC, Li YJ, Wang J, et al. Incidence of chronic kidney disease after orthotopic liver transplantation in a Chinese cohort. Clin Exp Nephrol. 2020;24:806–12.CrossRef
10.
go back to reference Lamattina JC, Foley DP, Mezrich JD, et al. Chronic kidney disease stage progression in liver transplant recipients. Clin J Am Soc Nephrol. 2011;6:1851–7.CrossRef Lamattina JC, Foley DP, Mezrich JD, et al. Chronic kidney disease stage progression in liver transplant recipients. Clin J Am Soc Nephrol. 2011;6:1851–7.CrossRef
11.
go back to reference Bahirwani R, Forde KA, Mu Y, et al. End-stage renal disease after liver transplantation in patients with pre-transplant chronic kidney disease. Clin Transpl. 2014;28:205–10.CrossRef Bahirwani R, Forde KA, Mu Y, et al. End-stage renal disease after liver transplantation in patients with pre-transplant chronic kidney disease. Clin Transpl. 2014;28:205–10.CrossRef
12.
go back to reference Kang GW, Lee IH, Ahn KS, et al. One-year follow-up of the changes in renal function after liver transplantation in patients without chronic kidney disease. Transplant Proc. 2016;48:1190–3.CrossRef Kang GW, Lee IH, Ahn KS, et al. One-year follow-up of the changes in renal function after liver transplantation in patients without chronic kidney disease. Transplant Proc. 2016;48:1190–3.CrossRef
13.
go back to reference Campo A. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:2563–5.CrossRef Campo A. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:2563–5.CrossRef
14.
go back to reference Hilmi IA, Damian D, Al-Khafaji A, et al. Acute kidney injury following orthotopic liver transplantation: incidence, risk factors, and effects on patient and graft outcomes. Br J Anaesth. 2015;114:919–26.CrossRef Hilmi IA, Damian D, Al-Khafaji A, et al. Acute kidney injury following orthotopic liver transplantation: incidence, risk factors, and effects on patient and graft outcomes. Br J Anaesth. 2015;114:919–26.CrossRef
15.
go back to reference Leithead JA, Ferguson JW, Bates CM, et al. Chronic kidney disease after liver transplantation for acute liver failure is not associated with perioperative renal dysfunction. Am J Transplant. 2011;11:1905–15.CrossRef Leithead JA, Ferguson JW, Bates CM, et al. Chronic kidney disease after liver transplantation for acute liver failure is not associated with perioperative renal dysfunction. Am J Transplant. 2011;11:1905–15.CrossRef
16.
go back to reference Rahman S, Davidson BR, Mallett SV. Early acute kidney injury after liver transplantation: predisposing factors and clinical implications. World J Hepatol. 2017;9(18):823–32.CrossRef Rahman S, Davidson BR, Mallett SV. Early acute kidney injury after liver transplantation: predisposing factors and clinical implications. World J Hepatol. 2017;9(18):823–32.CrossRef
17.
go back to reference Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl. 2004;10(2):301–9.CrossRef Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl. 2004;10(2):301–9.CrossRef
18.
go back to reference National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1). National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1).
19.
go back to reference KDIGO AKI Work Group. Kidney Disease: Improving Global Outcomes (KDIGO) CKD work group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150. KDIGO AKI Work Group. Kidney Disease: Improving Global Outcomes (KDIGO) CKD work group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
20.
go back to reference Yap W-K, Shih M-C, Kuo C, et al. Development and validation of a nomogram for assessing survival in patients with metastatic lung cancer referred for radiotherapy for bone metastases. JAMA Netw Open. 2018;1:e183242.CrossRef Yap W-K, Shih M-C, Kuo C, et al. Development and validation of a nomogram for assessing survival in patients with metastatic lung cancer referred for radiotherapy for bone metastases. JAMA Netw Open. 2018;1:e183242.CrossRef
21.
go back to reference Leithead JA, Ferguson JW, Hayes PC. Modifiable patient factors are associated with the late decline in renal function following liver transplantation. Clin Transpl. 2012;26:E316–23.CrossRef Leithead JA, Ferguson JW, Hayes PC. Modifiable patient factors are associated with the late decline in renal function following liver transplantation. Clin Transpl. 2012;26:E316–23.CrossRef
22.
go back to reference Tada K, Maeda T, Takahashi K, et al. Association between serum uric acid and new onset and progression of chronic kidney disease in a Japanese general population: Iki epidemiological study of atherosclerosis and chronic kidney disease. Clin Exp Nephrol. 2021;25:751–9.CrossRef Tada K, Maeda T, Takahashi K, et al. Association between serum uric acid and new onset and progression of chronic kidney disease in a Japanese general population: Iki epidemiological study of atherosclerosis and chronic kidney disease. Clin Exp Nephrol. 2021;25:751–9.CrossRef
23.
go back to reference Kaewput W, Thongprayoon C, Rangsin R, et al. Association between serum uric acid and chronic kidney disease in patients with hypertension: a multicenter nationwide cross-sectional study. J Evid Based Med. 2019;12:235–42.CrossRef Kaewput W, Thongprayoon C, Rangsin R, et al. Association between serum uric acid and chronic kidney disease in patients with hypertension: a multicenter nationwide cross-sectional study. J Evid Based Med. 2019;12:235–42.CrossRef
24.
go back to reference Yang H, Chen Q, Huang A, et al. The impact of hyperuricemia on long-term clinical outcomes of renal transplant recipients: a systematic review and meta-analysis. J Pharm Pharm Sci. 2021;24:292–307.CrossRef Yang H, Chen Q, Huang A, et al. The impact of hyperuricemia on long-term clinical outcomes of renal transplant recipients: a systematic review and meta-analysis. J Pharm Pharm Sci. 2021;24:292–307.CrossRef
25.
go back to reference Feig DI, Madero M, Jalal DI, et al. Uric acid and the origins of hypertension. J Pediatr. 2013;162:896–902.CrossRef Feig DI, Madero M, Jalal DI, et al. Uric acid and the origins of hypertension. J Pediatr. 2013;162:896–902.CrossRef
26.
go back to reference Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–6.CrossRef Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–6.CrossRef
27.
go back to reference Xu C, Lu A, Lu X, et al. Activation of renal (pro)renin receptor contributes to high fructose-induced salt sensitivity. Hypertension. 2017;69(2):339–48.CrossRef Xu C, Lu A, Lu X, et al. Activation of renal (pro)renin receptor contributes to high fructose-induced salt sensitivity. Hypertension. 2017;69(2):339–48.CrossRef
28.
go back to reference Eräranta A, Kurra V, Tahvanainen AM, et al. Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. J Hypertens. 2008;26(8):1661–8.CrossRef Eräranta A, Kurra V, Tahvanainen AM, et al. Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. J Hypertens. 2008;26(8):1661–8.CrossRef
29.
go back to reference Isaka Y, Takabatake Y, Takahashi A, Saitoh T, Yoshimori T. Hyperuricemia-induced inflammasome and kidney diseases. Nephrol Dial Transplant. 2016;31(6):890–6. Isaka Y, Takabatake Y, Takahashi A, Saitoh T, Yoshimori T. Hyperuricemia-induced inflammasome and kidney diseases. Nephrol Dial Transplant. 2016;31(6):890–6.
30.
go back to reference Chiu T-H, Wu P-Y, Huang J-C, et al. Hyperuricemia is associated with left ventricular dysfunction and inappropriate left ventricular mass in chronic kidney disease. Diagnostics. 2020;10:514.CrossRef Chiu T-H, Wu P-Y, Huang J-C, et al. Hyperuricemia is associated with left ventricular dysfunction and inappropriate left ventricular mass in chronic kidney disease. Diagnostics. 2020;10:514.CrossRef
31.
go back to reference Lee C-L, Wang J-S. Effects of hyperuricemia on incident renal replacement therapy and all-cause mortality among patients with chronic kidney disease stages 3-5: a retrospective cohort study. Sao Paulo medical journal =. Rev Paul Med. 2019;137:523–9. Lee C-L, Wang J-S. Effects of hyperuricemia on incident renal replacement therapy and all-cause mortality among patients with chronic kidney disease stages 3-5: a retrospective cohort study. Sao Paulo medical journal =. Rev Paul Med. 2019;137:523–9.
32.
go back to reference Pons JA, Ramírez P, Revilla-Nuin B, et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin Transpl. 2009;23:329–36.CrossRef Pons JA, Ramírez P, Revilla-Nuin B, et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin Transpl. 2009;23:329–36.CrossRef
33.
go back to reference Malheiro J, Almeida M, Fonseca I, et al. Hyperuricemia in adult renal allograft recipients: prevalence and predictors. Transplant Proc. 2012;44:2369–72.CrossRef Malheiro J, Almeida M, Fonseca I, et al. Hyperuricemia in adult renal allograft recipients: prevalence and predictors. Transplant Proc. 2012;44:2369–72.CrossRef
34.
go back to reference Maheshwari A, Mishra R, Thuluvath PJ. Post-liver-transplant anemia: etiology and management. Liver Transpl. 2004;10(2):165–73.CrossRef Maheshwari A, Mishra R, Thuluvath PJ. Post-liver-transplant anemia: etiology and management. Liver Transpl. 2004;10(2):165–73.CrossRef
35.
go back to reference Kalisvaart M, Schlegel A, Trivedi PJ, et al. Chronic kidney disease after liver transplantation: impact of extended criteria grafts. Liver Transpl. 2019;25:922–33.CrossRef Kalisvaart M, Schlegel A, Trivedi PJ, et al. Chronic kidney disease after liver transplantation: impact of extended criteria grafts. Liver Transpl. 2019;25:922–33.CrossRef
36.
go back to reference Cullaro G, Pisa JF, Brown RS, et al. Early postoperative neutrophil gelatinase-associated lipocalin predicts the development of chronic kidney disease after liver transplantation. Transplantation. 2018;102:809–15.CrossRef Cullaro G, Pisa JF, Brown RS, et al. Early postoperative neutrophil gelatinase-associated lipocalin predicts the development of chronic kidney disease after liver transplantation. Transplantation. 2018;102:809–15.CrossRef
37.
go back to reference Levitsky J, Asrani SK, Klintmalm G, et al. Discovery and validation of a biomarker model (PRESERVE) predictive of renal outcomes after liver transplantation. Hepatology. 2020;71:1775–86.CrossRef Levitsky J, Asrani SK, Klintmalm G, et al. Discovery and validation of a biomarker model (PRESERVE) predictive of renal outcomes after liver transplantation. Hepatology. 2020;71:1775–86.CrossRef
38.
go back to reference Weismüller TJ, Lerch C, Evangelidou E, et al. A pocket guide to identify patients at risk for chronic kidney disease after liver transplantation. Transpl Int. 2015;28:519–28.CrossRef Weismüller TJ, Lerch C, Evangelidou E, et al. A pocket guide to identify patients at risk for chronic kidney disease after liver transplantation. Transpl Int. 2015;28:519–28.CrossRef
Metadata
Title
Prediction of chronic kidney disease after orthotopic liver transplantation: development and validation of a nomogram model
Authors
Dandan Guo
Huifang Wang
Jun Liu
Hang Liu
Ming Zhang
Zixuan Fu
Xuemei Liu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-021-02650-1

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.